Severe Immune Hemolytic Anemia due to Pemetrexed in a Patient with Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1423-0313|88|5-6|242-244

ISSN： 0031-7012

Source： Pharmacology, Vol.88, Iss.5-6, 2011-10, pp. : 242-244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pemetrexed for Previously Treated Patients with Non-Small Cell Lung Cancer and Differences in Efficacy according to Thymidylate Synthase Expression

By  

Chemotherapy, Vol. 58, Iss. 4, 2012-11 ,pp. : 313-320

Karger

Access to resources Recommend Favorite

A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 61, Iss. 3, 2016-01 ,pp. : 144-147

Karger

Access to resources Recommend Favorite

Schedule-Dependent Synergistic Effect of Pemetrexed Combined with Gemcitabine against Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer Cell Lines

By  

Chemotherapy, Vol. 54, Iss. 3, 2008-06 ,pp. : 166-175

Karger

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 472-477

Karger

Access to resources Recommend Favorite

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

By  

Chemotherapy, Vol. 61, Iss. 1, 2015-0 ,pp. : 41-50

Karger

Access to resources Recommend Favorite